As NPM1mut/FLT3-ITD AML patients have relatively poor outcomes due to high relapse rates [26], we envision that anti-CD123 immunotherapy could be of particular benefit for this specific subset of patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.